Research progress on factors affecting the sensitivity of breast cancer to radiotherapy: a narrative review.

IF 1.5 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2024-07-31 Epub Date: 2024-07-16 DOI:10.21037/tcr-24-71

Qian Zhang, Fusheng Qian, Mengjie Cai, Ruijie Liu, Manping Chen, Zhitong Li, Ying Chen, Nannan Lu

{"title":"Research progress on factors affecting the sensitivity of breast cancer to radiotherapy: a narrative review.","authors":"Qian Zhang, Fusheng Qian, Mengjie Cai, Ruijie Liu, Manping Chen, Zhitong Li, Ying Chen, Nannan Lu","doi":"10.21037/tcr-24-71","DOIUrl":null,"url":null,"abstract":"Background and objective: Radiation therapy (RT) is one of the important components of comprehensive treatment for breast cancer and has important value in improving the control rate of local areas, reducing the chance of recurrence and metastasis after breast cancer surgery, delaying disease progression, and improving the survival of breast cancer patients. The factors that affect the RT sensitivity of breast cancer are important. The above potential predictors of radiation efficacy can provide patients with a predictive method and therefore have significant value in clinical therapy. In this paper, we have summarised the predictive factors of radiotherapy sensitivity by reviewing recent research on breast cancer and focused on the following areas: tumor immune microenvironment (TIME), cancer stem cells, noncoding RNAs, signal transduction pathways, genes, etc. This review aims to provide theoretical basis and reference for improving the efficacy of radiotherapy and experimental individualized treatment of breast cancer.Methods: We searched the Web of Science database to identify clinical studies published between 2010 and January 2024 that investigated radiotherapy sensitivity. The main findings of the validated studies were summarised.Key content and findings: Improving the radiosensitivity of breast cancer is essential in the treatment of breast cancer. The radiosensitivity can be improved by modulating immune cells or immunomodulatory factors in the TIME, modulating signal transduction pathways, and other innovative combination therapy strategies. And we also summarized the predictive markers of breast cancer radiosensitivity.Conclusions: In this paper, we reviewed the literature and summarized the newest research advances on the radiosensitivity of breast cancer patients. This review paper includes the following six aspects: the immune microenvironment, tumor stem cells, signaling pathways, regulation of gene/protein expression, small molecule drugs, and predictive markers for radiosensitivity.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319974/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-71","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Radiation therapy (RT) is one of the important components of comprehensive treatment for breast cancer and has important value in improving the control rate of local areas, reducing the chance of recurrence and metastasis after breast cancer surgery, delaying disease progression, and improving the survival of breast cancer patients. The factors that affect the RT sensitivity of breast cancer are important. The above potential predictors of radiation efficacy can provide patients with a predictive method and therefore have significant value in clinical therapy. In this paper, we have summarised the predictive factors of radiotherapy sensitivity by reviewing recent research on breast cancer and focused on the following areas: tumor immune microenvironment (TIME), cancer stem cells, noncoding RNAs, signal transduction pathways, genes, etc. This review aims to provide theoretical basis and reference for improving the efficacy of radiotherapy and experimental individualized treatment of breast cancer.

Methods: We searched the Web of Science database to identify clinical studies published between 2010 and January 2024 that investigated radiotherapy sensitivity. The main findings of the validated studies were summarised.

Key content and findings: Improving the radiosensitivity of breast cancer is essential in the treatment of breast cancer. The radiosensitivity can be improved by modulating immune cells or immunomodulatory factors in the TIME, modulating signal transduction pathways, and other innovative combination therapy strategies. And we also summarized the predictive markers of breast cancer radiosensitivity.

Conclusions: In this paper, we reviewed the literature and summarized the newest research advances on the radiosensitivity of breast cancer patients. This review paper includes the following six aspects: the immune microenvironment, tumor stem cells, signaling pathways, regulation of gene/protein expression, small molecule drugs, and predictive markers for radiosensitivity.

查看原文本刊更多论文

乳腺癌放疗敏感性影响因素的研究进展：综述。

背景和目的：放射治疗（RT）是乳腺癌综合治疗的重要组成部分之一，在提高局部病灶的控制率、减少乳腺癌术后复发和转移的机会、延缓疾病进展、提高乳腺癌患者生存率等方面具有重要价值。影响乳腺癌 RT 敏感性的因素非常重要。上述潜在的放射疗效预测指标可以为患者提供一种预测方法，因此在临床治疗中具有重要价值。本文通过回顾近年来有关乳腺癌的研究，总结了放疗敏感性的预测因素，主要集中在以下几个方面：肿瘤免疫微环境（TIME）、癌症干细胞、非编码 RNA、信号转导通路、基因等。本综述旨在为提高乳腺癌放疗疗效和个体化治疗实验提供理论依据和参考：方法：我们检索了 Web of Science 数据库，以确定 2010 年至 2024 年 1 月间发表的研究放疗敏感性的临床研究。主要内容和结论提高乳腺癌的放射敏感性对乳腺癌的治疗至关重要。可以通过调节TIME中的免疫细胞或免疫调节因子、调节信号转导通路以及其他创新的联合治疗策略来提高放射敏感性。我们还总结了乳腺癌放射敏感性的预测指标：本文回顾了相关文献，总结了乳腺癌患者放射敏感性的最新研究进展。本综述包括以下六个方面：免疫微环境、肿瘤干细胞、信号通路、基因/蛋白表达调控、小分子药物和放射敏感性预测标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.